Dikhyaa Mohanty 
Bharat Biotech’s Covaxin for children in the age group of 2-18 year has been approved by the Subject Expert Committee on Coronavirus has granted emergency usage.
According to the official reports, Hyderabad-based Bharat Biotech had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September and submitted the trial data to the Drugs and Comptroller General of India (DCGI) at the start of this month.
The subject expert panel informed in a statement that after detailed deliberation, the committee recommended for grant of market authorization of the vaccine for the age group of 2 to 18 years for restricted use in emergency situation. The vaccine will be administered in two doses with a gap of 20 days between the first and second dose.
For the time being, WHO hasn’t granted any authorization for the emergency use to Covaxin and Bharat Biotech had reportedly submitted all documents required for the listing to the WHO by July 9, and the WHO review process, which takes close to six weeks, had commenced by July-end.
Article Written By Dikhya Mohanty
Pic Courtesy – Google
